2 completed, 1 active not recruiting. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Camurus AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD CAM2029, Placebo - Polycystic Liver Disease | Phase 2 / Phase 3 | Active not recruiting | Camurus AB | 71 | 2022-06-28 | 2026-06-01 |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) octreotide FluidCrystal® injection depot - Acromegaly, Neuroendocrine Tumors | Phase 2 | Completed | Camurus AB | 12 | 2015-01-01 | 2017-12-15 |
| Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer leuprolide acetate FluidCrystal® injection depot, leuprolide acetate - Prostate Cancer | Phase 2 | Completed | Camurus AB | 51 | 2014-09-01 | 2017-04-25 |
Acromegaly (1) · Neuroendocrine Tumors (1) · Polycystic Kidney, Autosomal Dominant (1) · Polycystic liver disease (1) · Prostatic Neoplasms (1) · Serotonin Syndrome (1)
Leuprolide (1) · luprolide acetate gel depot (1)
Germany (2) · Belgium (1) · Finland (1) · France (1) · Hungary (1) · Italy (1) · Netherlands (1) · Sweden (1) · United States (1)
Joost Drenth, MD (1) · Marianne Pavel, Professor (1) · Teuvo Tammela, Prof (1)